Pardes Biosciences Inc (PRDS) Financials

$2.16

$0.00 (0.00%)

As on 08-Sep-2023 09:30EDT

Market cap

$134 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Operating Expenses	82.88	99.82	38.49	--	--	--
Operating Profit (EBIT)	-84.61	-99.82	-38.49	--	--	--
Other Income	--	--	--	--	--	--
Profit before Tax	-76.14	-96.63	-38.52	--	--	--
Provision for Tax	20.14	-3.18	0.03	--	--	--
Profit after Tax (Net Income)	-96.28	-93.45	-38.55	--	--	--
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-65.36	-96.63	-38.52	-15.61	--	--

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	155.39	180.20	266.29	-13.01	--	--
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	4.93	2.39	1.39	--	--
Current Liabilities	1.93	20.43	8.97	16.61	--	--
Total Liabilities	159.24	200.62	275.26	3.60	--	--

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	--	0.22	--	--	--	--
Current Assets	157.31	200.40	275.26	3.60	--	--
Total Assets	159.24	200.62	275.26	3.60	--	--
Total Debt*	--	--	--	--	--	--
Net Current Assets	155.39	179.98	266.29	-13.01	--	--

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-71.98	-36.92	-4.27	--	--
Cash Flow from Investing Activities	--	-137.02	--	--	--	--
Cash from Financing Activities	--	-0.40	302.19	8.36	--	--
Net Cash Inflow / Outflow	--	-209.39	265.27	--	--	--

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-1.62	-1.57	-0.62	--	--	--
Cash EPS ($)	--	-1.57	-0.62	--	--	--
Adjusted Book Value ($)	--	3.04	4.27	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-1.21	-0.59	--	--	--
Free Cash Flow per Share ($)	--	-1.21	-0.59	--	--	--

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	-41.86	-30.44	--	--	--
ROE (%)	-57.38	-41.86	-30.44	--	--	--
ROA (%)	-47.63	-39.28	-27.65	--	--	--
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	35.52	-159.35	-503.68	--	--	--
Net Profit Growth (%)	-28.97	-142.43	--	--	--	--
EPS Growth (%)	-26.56	-1.55	--	--	--	--
Book Value Growth (%)	-33.13	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-1.07	-26.49	--	--	--
Price / Book Value	0.37	0.56	3.83	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1.53	1.04	19.55	--	--	--
Close Price ($)	1.81	1.69	16.37	--	--	--
High Price ($)	3.93	17.50	17.76	--	--	--
Low Price ($)	0.75	0.75	9.64	--	--	--
Market Cap ($ Cr)	133.95	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	--	--	--	--	--
Short term debt to equity ratio	--	--	--	--	--	--
Current Ratio	81.72	9.81	30.70	0.22	--	--
Quick Ratio	81.72	--	--	--	--	--
Interest Coverage	-22.81	-31.36	-1,282.93	--	--	--

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	--	--	--	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.